Emerging Target STARD10 in HER2+ Breast Cancer: Strategic Implications for Roche
Oncology · Breast Cancer • Other • Jun 16, 2026
Assessment confidence: 59% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
Executive Thesis
The amplification of genes adjacent to F3 in pancreatic adenocarcinoma is linked to worse patient outcomes, highlighting the need for enhanced patient stratification and potential new therapeutic targets. This could significantly impact treatment strategies and market positioning for companies involved in oncology. Regulatory context from FDA (FDA AP — PHESGO (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (9 high-relevance).
Strategic Assessment
The strongest clinical anchor is The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer (ClinicalTrials.gov), entity match (oncology). In Oncology · Pancreatic Adenocarcinoma, 6 regulatory and 4 competitive items passed relevance filtering for Amgen. Identifying biomarkers associated with poor prognosis could lead to the development of targeted therapies, influencing market share and revenue potential in the competitive oncology landscape.
Competitive Pressure
The most relevant competitive pressure comes from FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment (Humanexa Signals) — entity match (keytruda). Secondary pressure from Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC. These findings suggest potential biomarkers for poor prognosis in pancreatic adenocarcinoma, which could influence treatment strategies and patient management.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — PHESGO (SUPPL) (FDA). Regulatory pathway relevance (bla). If gene amplification is validated as a biomarker, it may necessitate changes in clinical trial designs and regulatory submissions for new therapies targeting pancreatic adenocarcinoma.
Key Risks
- Elevated medium regulatory exposure for Amgen could delay market entry or constrain labeling if agency review intensifies.
- Signal severity is high — leadership review is warranted.
- Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Amgen through agency review timelines and labeling constraints if follow-through weakens.
- Clinical risk from ClinicalTrials.gov (Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study) could weigh on Amgen through efficacy or safety read-through uncertainty if follow-through weakens.
- Clinical risk from ClinicalTrials.gov (Radiotherapy After Prostatectomy for Node Positive Prostate Cancer) could weigh on Amgen through efficacy or safety read-through uncertainty if follow-through weakens.
Key Opportunities
- Identifying biomarkers associated with poor prognosis could lead to the development of targeted therapies, influencing market share and revenue potential in the competitive oncology landscape.
- Oncology · Renal Cell Carcinoma · Trial Update · This outcome may impact the competitive positioning of Merck and Eisai's combination therapies in the RCC market, potentially favoring alternative treatments that demonstrate better efficacy.
- Oncology · NRG1 Fusion-Positive Cholangiocarcinoma · Regulatory Approval · This approval adds a new treatment option in a niche market for an ultra-rare cancer, potentially impacting competitors focused on cholangiocarcinoma therapies.
- Upside for Amgen may improve if Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.
- Upside for Amgen may improve if Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (ClinicalTrials.gov) delivers favorable follow-through.
What Would Change This Assessment
- This becomes more urgent if Monitor ongoing research into gene amplification effects on treatment outcomes and potential targeted therapies for pancreatic adenocarcinoma.
- Additional medium- or high-relevance evidence would materially upgrade this assessment.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — HERCEPTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View sourceFDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View sourceFDA AP — HERCEPTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View sourceSunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View sourceRetrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceSafety, Feasibility, and Outcomes of Early Rehabilitation After Breast Cancer Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceOpen Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTesting the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceBreast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRadiotherapy After Prostatectomy for Node Positive Prostate Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
No evidence in this category.
Amplification of pro-proliferative genes adjacent to the F3 gene in pancreatic adenocarcinoma is associated with worse outcomes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceThe regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceGenetic variants of the transporter SLC22A4 affect the abundance and survival of Fusobacterium nucleatum in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceA relative methylation ordering biomarker of lactylation-related genes predicts prognosis and therapeutic response in cutaneous melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceUBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceGut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePredictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceContrasting dietary patterns remodel gut microbial function and generate multi-omic signatures associated with cardiometabolic markers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Related Signals
- Targeting Macrophage Cytokine Circuit Offers New Strategy Against TNBC Metastasis
Other
- CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation
Other
- Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation
Other
- Shikonin Induces Ferroptosis in DLBCL via lncRNA ADPGK-AS1 Downregulation
Other
- MITF-Driven Plasticity in Melanoma: Key to Overcoming Therapy Resistance
Other
- FCGR2B Targeting Enhances Anti-Tumor Activity of Macrophages in Melanoma
Other
- Systematic review on EGFR alterations in recurrent glioblastoma therapy response
Other
- RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
Other
- Role of GSH and H2S in Cancer Metabolism: Implications for Anticancer Strategies
Other
- STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism
Other
- Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis
Other
- Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
Other
- Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors
Other
- Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma
Other
- Non-coding RNAs as regulators of aerobic glycolysis in pancreatic ductal adenocarcinoma
Other
Related Competitors
AstraZeneca — trastuzumab
Pressure: high
AstraZeneca is a regulatory competitive threat because recent agency-facing activity on trastuzumab in Oncology · Breast Cancer may reset approval benchmarks and timeline expectations for Roche.
Related Regulatory Precedents
FDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
SourceFDA
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
SourceFDA
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
FDA AP — HERCEPTIN (SUPPL)
Application BLA103792. Sponsor: GENENTECH. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TRASTUZUMAB.
SourceFDA
FDA AP — ENHERTU (SUPPL)
Application BLA761139. Sponsor: DAIICHI SANKYO. Submission status: AP. Submission type: SUPPL. Review priority: PRIORITY. Active ingredients: FAM-TRASTUZUMAB DERUXTECAN-NXKI.
SourceFDA
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
SourceFDA
Sunscreen: How to Help Protect Your Skin from the Sun
How you use sunscreens, and what other protective measures you take, make a difference in how well you are able to protect yourself and your family from sunburn, skin cancer, early skin aging and other risks of overexposure to the sun.
SourceFDA
FDA AP — HERCEPTIN HYLECTA (SUPPL)
Application BLA761106. Sponsor: GENENTECH INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TRASTUZUMAB AND HYALURONIDASE-OYSK.
SourceFDA
FDA AP — ONTRUZANT (SUPPL)
Application BLA761100. Sponsor: SAMSUNG BIOEPIS CO LTD. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TRASTUZUMAB-DTTB.
SourceFDA
FDA AP — HERCEPTIN (SUPPL)
Application BLA103792. Sponsor: GENENTECH. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TRASTUZUMAB.
Source